(Q38092470)

28 August 2017

title

Clinical development of Modified Vaccinia virus Ankara vaccines (English)

1 reference

28 August 2017

0 references

Vaccinia virus

1 reference

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

31

1 reference

28 August 2017

issue

39

1 reference

28 August 2017

page(s)

4241-4246

1 reference

Poxvirus genomes: a phylogenetic analysis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Smallpox vaccines for biodefense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Smallpox vaccine safety is dependent on T cells and not B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Introduction of the Six Major Genomic Deletions of Modified Vaccinia Virus Ankara (MVA) into the Parental Vaccinia Virus Is Not Sufficient To Reproduce an MVA-Like Phenotype in Cell Culture and in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

A protein particle vaccine containing multiple malaria epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

T-cell-inducing vaccines - what's the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

The global eradication of smallpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.03.020

1 reference

28 August 2017

1 reference